Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10

Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...
June 03, 2019 16:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019

No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
June 03, 2019 09:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019

No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...
May 09, 2019 08:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Appoints Bruce Horowitz as Chief Operating Officer

KNOXVILLE, TN, May 09, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Bruce Horowitz as the Company’s Chief Operating Officer. Mr. Horowitz had previously served...
April 17, 2019 16:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...
March 25, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Appoints Heather Raines, CPA as Chief Financial Officer

KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously...
March 21, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10

KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
February 19, 2019 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy

Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...
February 12, 2019 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA

KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
January 29, 2019 08:30 ET | Source: Provectus Biopharmaceuticals Inc.

ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY

- 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival; ILI is historical...